Who owns NBRVF - NABRIVA THERAPEUTICS PLC - SHS NEW 2022 based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) Institutional Ownership

Q: What is CUSIP G63637139?

CUSIP G63637139 is the security identifier used in SEC filing datasets for NBRVF - NABRIVA THERAPEUTICS PLC - SHS NEW 2022.

CUSIP: G63637139

13F Institutional Holders and Ownership History from Q3 2022 to Q3 2023

Type / Class: Equity / SHS NEW 2022
Symbol: NBRVF

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Investment Quick Answers

What is CUSIP G63637139?
CUSIP G63637139 identifies NBRVF - NABRIVA THERAPEUTICS PLC - SHS NEW 2022 in SEC 13F datasets.

Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.

Continue Investment Research

Latest 13F filings for new institutional portfolio disclosures.
Latest Schedule 13D/13G reports for activist and beneficial ownership updates.
Latest 10-Q/10-K reports to cross-check issuer fundamentals.
Recent insider transactions for management buying/selling context.
SEC investors directory and top value investors for manager-level discovery.
All institutional ownership pages to compare adjacent CUSIP pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP G63637139:

Q3 2023 (0 holders) Q2 2023 (8 holders) Q1 2023 (11 holders) Q4 2022 (11 holders) Q3 2022 (6 holders)

Institutional Holders of NABRIVA THERAPEUTICS PLC - SHS NEW 2022 (NBRVF) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Price (Median)	Investors
2023 Q3	0	$0	-$97,317		0
2023 Q2	57,627	$97,317	-$50,477	$1.52	8
2023 Q1	86,438	$150,695	-$18,598	$1.75	11
2022 Q4	95,811	$181,549	+$47,184	$1.89	11
2022 Q3	70,252	$146,000	+$146,000	$2.07	6